Metoclopramide (Metoclopramide Hydrochloride)

Metoclopramide acts on the central dopaminergic pathways and the gastrointestinal tract to relieve several conditions:

• Nausea and vomiting: reduces episodes caused by chemotherapy, surgery, or other triggers.
• Gastroparesis: enhances gastric motility to improve stomach emptying.
• Migraine‑associated nausea: alleviates nausea that accompanies migraine attacks.
• Facilitation of gastric emptying: used pre‑operatively or before diagnostic procedures to speed gastric clearance.

• Metoclopramide antagonizes dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the vomiting reflex. It also blocks peripheral D2 receptors and stimulates muscarinic receptors, leading to increased acetylcholine release, which promotes coordinated gastrointestinal smooth‑muscle contractions and accelerates gastric emptying.

Metoclopramide may cause a range of adverse reactions, most of which are dose‑related or transient.

Common Side Effects

• Drowsiness: mild sedation or fatigue.
• Restlessness: feeling of inner tension or agitation.
• Diarrhea: loose stools due to increased motility.
• Dry mouth: reduced salivation.
• Headache: mild to moderate intensity.
• Dystonia (especially in young adults): involuntary muscle contractions.

Serious or Rare Side Effects

• Extrapyramidal symptoms: severe movement disorders requiring medical attention.
• Tardive dyskinesia: persistent involuntary movements after prolonged use.
• Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity.
• Depression or suicidal thoughts: mood alterations.
• Allergic reactions: rash, itching, or swelling.
• Hyperprolactinemia: elevated prolactin causing galactorrhea or menstrual changes.

When prescribing Metoclopramide, clinicians should consider several safety measures:

• Contraindications: avoid in patients with known hypersensitivity to the drug.
• Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Breastfeeding: assess risk‑benefit, as the drug may be excreted in milk.
• Elderly patients: start at the lowest effective dose and monitor for CNS effects.
• Prolonged therapy: limit duration to reduce risk of tardive dyskinesia.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Metoclopramide can alter the effectiveness or safety profile of several co‑administered medicines.

Major Interactions (Avoid)

• Anticholinergic agents: may reduce pro‑kinetic effect.
• CNS depressants (e.g., opioids, benzodiazepines): increase sedation and respiratory depression risk.
• MAO inhibitors: heightened risk of extrapyramidal symptoms.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., codeine, tramadol): possible altered metabolism.
• Digoxin: may increase serum levels.
• Antidepressants (SSRIs, SNRIs): monitor for additive serotonergic effects.
• Antihistamines: may blunt anti‑emetic efficacy.